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Microglial cells are extremely plastic and undergo a variety of CNS-prompted shape changes
relative to their location and current role. Signaling molecules from neurons also regulate
microglial cytokine production. Neurons are known to employ the endogenous cannabinoid
system to communicatewith other cells of theCNS.N -arachidonoyl glycine (NAGly) and 9 -
tetrahydrocannabinol ( 9 -THC) signaling via GPR18 has been introduced as an important
new target in microglial–neuronal communication. Our hypothesis is that endogenous
NAGly-GPR18 signaling regulates phenotypic shape and cytokine production in microglia,
and is mimicked by 9 -THC in the BV-2 microglia model system. BV-2 microglia were
exposed to NAGly and 9 -THC orVh for 12 h, which resulted in signiﬁcant differences in the
cell morphologies expressed. Cannabidiol (CBD) was effective at antagonizing the effects
of both NAGly and 9 -THC. Using ELISA-based microarrays, BV-2 microglia were exposed
to NAGly and 9 -THC or Vh for 3 h and the presence of 40 cytokines in the culture media
quantiﬁed. Production of Axl, CD40, IGF-I, OPN, and Pro-MMP-9 were signiﬁcantly altered
by NAGly and 9 -THC, and antagonized by CBD. These data add to an emerging proﬁle
that emphasizes NAGly as a component of an endogenous system present in the CNS
that tightly integrates microglial proliferation, recruitment, and adhesion with neuron–glia
interactivity and tissue remodeling.
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INTRODUCTION
Microglial cells are extremely plastic and undergo a variety of
shape changes relative to their location and current role (Block
et al., 2007; Colton and Wilcock, 2010). Ramiﬁed microglia pos-
sess a characteristic form composed of long branching processes
that are very sensitive to alterations in the local microenvironment
(Fetler and Amigorena, 2005; Raivich, 2005). Amoeboid microglia
scavenge CNS plaque and foreign agents and mediate cytotoxic
and inﬂammatory signaling (Gordon,2003; Fetler andAmigorena,
2005; Raivich, 2005; Garden and Moller, 2006). Microglia have a
signiﬁcant impact on overall CNS stability andmay act as an essen-
tial link in the interaction of cytokines with neurons (Zhang et al.,
2003). In both developmental and post-developmental contexts,
microglia discriminately engulf and eliminate dead or dying neu-
rons. They are especially prevalent during rewiring of the brain
when there are large amounts of extracellular apoptotic debris to
remove.
These processes must be tightly controlled in order to sustain
the least possible collateral damage to adjacent neurons. Indeed,
microglial activity is not only orchestrated to exacting standards,
but the coupling between the death of neurons and their degra-
dation by microglia is both striking and swift. This remarkable
relationship suggests a fast-acting communication between neu-
rons and microglia, such that the microglia are forewarned of
the speciﬁc task (i.e., apoptosis, infection, or damage). Once
the phagocytic task of amoeboid microglia is complete a return
to the resting (i.e., multi-branched, surveillant) form is usually
observed. Yet, microglia are also implicated in virtually all CNS
neuropathological processes, where they become highly reactive
to dying neurons and provoke sustained secondary neurotoxicity
(Carson, 2002; Eikelenboom et al., 2002; Streit, 2002; Danton and
Dietrich, 2003; van Rossum and Hanisch, 2004). This extreme
dichotomy of behavior underscores the importance of under-
standing the speciﬁc signaling systems that both recruit and
instruct microglia to adapt their phenotype selectively in response
to damaged/dying/apoptotic neurons, and which are foundational
to our ability to monitor and manage dysregulated microglial
activity.
Neurons are known to employ the endogenous cannabinoid
system to communicate with other cells of the CNS. Walter et al.
(2003) reported the involvement of the endogenous cannabinoid
signaling in recruiting microglia toward dying neurons in vitro.
Recently the pharmacology of N-arachidonoyl glycine (NAGly),
various cannabinoids [most notably 9-tetrahydrocannabinol
(9-THC)] and other signaling ligands at GPR18 receptors
has been described. During the same timeframe, NAGly-
GPR18 signaling was also introduced as an important new
target inmicroglial–neuronal communication (seeMcHugh,2012;
McHugh et al., 2012a,b for review). NAGly is synthesized in the
CNS primarily from AEA via a fatty acid amide hydrolase (FAAH)
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dependent pathway and can be prevented by URB597, an irre-
versible inhibitor of FAAH (Bradshaw et al., 2009). It is ineffective
as an agonist at either CB1 or CB2 receptors despite the obvi-
ous structural overlap with AEA (Járai et al., 1999; Begg et al.,
2005; Mackie and Stella, 2006). Instead, NAGly acts as a high
afﬁnity ligand for the Gi/o-coupled GPCR GPR18 (Kohno et al.,
2006; McHugh et al., 2010, 2012a,b; McHugh, 2012) and a par-
tial agonist of Gq/11−coupled GPR92 receptors (Oh et al., 2008).
9-THC is a well-established agonist at Gi/o-coupled cannabi-
noid CB1 and CB2 receptors (for review, see Pertwee et al.,
2010). More recent investigations have raised the prospect of
9-THC signaling via non-CB1 and non-CB2 GPCRs, includ-
ing GPR55 and GPR18, although the current pharmacology of
GPR55 is complicated and inconsistent (Pertwee et al., 2010).
Here, we explore the hypothesis that NAGly–GPR18 signal-
ing regulates morphological and cytokine signaling plasticity,
which is mimicked by 9-THC in the BV-2 microglia model
system.
MATERIALS AND METHODS
TEST COMPOUNDS
Cannabinoids and related lipids are practically stable during
storage, with concentration changes attributed to oxidation, tem-
perature effects, and lipophilic binding. The lipid compounds
tested in this study were prepared in 100% DMSO to a stock
concentration of 100 mM, aliquoted and kept at −20◦C. Fresh
aliquots were used for each independent experiment. Compounds
were serially diluted to achieve the desired ﬁnal working concen-
trations, where each contained 0.1% DMSO as vehicle. NAGly
was purchased from Cayman Chemicals (Farmingdale, NY, USA),
lipopolysaccharide (LPS), and phorbol 12- myristate 13- acetate
(PMA) from Sigma-Aldritch (St. Louis, MO, USA). 9-THC and
Cannabidiol (CBD) were provided by Dr. Ken Mackie, Indiana
University.
CELLS IN CULTURE
The mouse microglial cell line BV-2 (a gift from Dr. N. Stella; Uni-
versity of Washington, Seattle), which was originally generated by
immortalizing primary microglia (Blasi et al., 1990), were grown
in high glucose DMEM (Gibco, USA) supplemented with FBS
(5%), penicillin (100 units/ml), streptomycin (100 μg/ml), and
L-glutamine (0.292 mg/ml). Cells were passaged every 2–3 days
for a maximum of 30 passages. Media was replaced with serum-
free Ham’s F-12 phenol red-free media (Gibco, USA), supple-
mented with penicillin (100 units/ml), streptomycin (100 μg/ml)
and L-glutamine (0.292 mg/ml), 16 h prior to the start of
experiments.
BV-2 MORPHOLOGY EXPERIMENTS
BV-2 microglia were plated using serum-free Ham’s F-12 phenol
red-free media on 25 mm × 75 mm glass microscope slides that
had been pre-coated for 1 h with 1 μg/ml poly-D-lysine. A coated
microscope slide was placed in a 10 cm Petri dish then 1 ml of
cell suspension (5 × 105 cells/ml) was placed onto the center of
the slide using a Pasteur pipette. Then an additional 11 ml of the
Ham’s F-12 media was added to the dish together with Vh or test
compound. Cells were incubated for 12 h (5% CO2 atmosphere
at 37◦C) with Vh control (0.1% DMSO), 10 nM NAGly, 10 nM
9-THC, 100 nM CBD, 10 nM NAGly + 100 nM CBD, or 10 nM
9-THC+ 100nMCBD. 10nMPMAwasused as positive control.
Each condition was tested in triplicate per individual experiment.
The media was removed and replaced for 20 m with 12 ml of
cytoskeleton buffer with sucrose and formaldehyde. This buffer
consisted of 10 mM 2-N-morpholino ethanesulfonic acid (MES),
138mMKCl, 3mMMgCl2, 2mMEGTA in 1 L of H2O,with its pH
adjusted to 6.1. It was stored at 4◦C in between use. 0.32 M sucrose
was added to a 50 ml aliquot of the solution prior to each experi-
ment and thoroughly vortexed. Next formaldehyde was added to
the aliquot to achieve a concentration of 3.7%. Following the 20 m
incubation, the slides were then washed with phosphate-buffered
saline (PBS) three times. Next, permount was pipetted onto the
slide and a glass coverslip placed on top. Slides were then put in
a dark drawer, where they were protected from light, and left to
dry for at least 24 h. Images from 10 random ﬁelds of view were
collected at x20 magniﬁcation using a Nikon 80i light microscope
from each microscope slide. Cell morphology was recorded and
categorized by multiple investigators who were blind to the treat-
ment condition into six categories: amoeboid, unipolar, bipolar,
tripolar, multipolar, and ﬂat. This amounted to 200+ cells per
individual treatment replicate. Categorization was based on the
number of processes that branched directly off the cell body. A cell
was considered to be unipolar if it has one process, bipolar two,
tripolar three, and multipolar four or more. The amoeboid and
ﬂat categories had zero processes. To distinguish between these,
cells that were overtly three-dimensional and irregularly rounded
were classed as amoeboid; while those with their cytoplasm spread
over a larger area, with wavy edges and little three-dimensional
depth were classed as ﬂat (Figure 1).
BV-2 CYTOKINE RELEASE EXPERIMENTS
∼ 90% conﬂuent BV-2 cells were incubated for 3 h (5%CO2 atmo-
sphere at 37◦C) in 3 ml serum-free Ham’s F-12 phenol red-free
media withVh control (0.1% DMSO), 10 nM and 100 nM NAGly,
10 and 100 nM 9-THC, 100 nM CBD, 10 nM NAGly + 100 nM
CBD, and 100 nM 9-THC + 100 nM CBD. 10 nM PMA was
used as positive control. 1 μg/ml LPS was used as positive control.
After the incubation, the culture media was carefully removed
(to minimize transferring any cells) and placed in 15 ml cen-
trifuge tubes. Tubes were left undisturbed on the bench for
10 min to allow any cell debris to settle to the bottom. 100 μl
of culture media was then collected and the presence of 40
cytokines quantiﬁed using Quantibody Mouse Cytokine Array 4
(RayBiotech, Inc.), Odyssey blocking buffer (Li-Cor #927-40000),
Li-Cor IRDye 800CW Streptavidin (#926-32230), and Odyssey
infra-red imager (Li-Cor Biosciences). The Quantibody kit is a
multiplexed, sandwich ELISA-based array that enables researchers
to accurately determine the concentration of multiple cytokines
simultaneously. Odyssey settings were: resolution, 21 μm; quality,
highest; focal offset, 1.0 mm; and intensity, 10 for the 800 nm
channel (the 700 nm channel was not required). The cytokines
tested by the array were as follows: AR, Axl, CD27L, CD30T,
CD40, CXCL16, EGF, E-selectin, Fractalkine, GITR,HGF, IGFBP-
2, IGFBP-3, IGFBP-5, IGFBP-6, IGF-I, IL-12p70, IL-17E, IL-17F,
IL-1ra, IL-2 Rα, IL-20, IL-23, IL-28, I-TAC,MDC,MIP-2, MIP-3α,
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FIGURE 1 | Examples of the six different BV-2 morphological shapes observed and categorized.
OPN,OPG,Prolactin, Pro-matrixmetallopeptidase-9 (Pro-MMP-
9), P-selectin, Resistin, SCF, SDF-1α, TPO, VCAM-1, VEGF, and
VEGF-D.
ANALYSIS OF DATA
All data are expressed as means ± s.e.mean and n = number
of independent experiments. Statistical analyses were performed
with GraphPad Prism 4 or SPSS. One-way ANOVA (p < 0.05)
with LSD post hoc test was run to determine signiﬁcance between
treatment conditions.
RESULTS
EFFECTS OF9-THC AND NAGly ON BV-2 MICROGLIAL MORPHOLOGY
Microglial cells are extremely plastic and exist in a variety of
morphologies, including: amoeboid, unipolar, bipolar, tripolar,
multipolar, and ﬂat, which are illustrated in Figure 1. At rest,
BV2 microglia display primarily an amoeboid morphology (44%)
with varying degrees of branched morphologies (Table 1). Data
here replicated previous ﬁndings that 10 nM PMA induced a
shift in morphology from one that was round and amoeboid to
a non-round form with cytoplasmic extensions (Table 1). Like-
wise, 10 nM NAGly and 10 nM 9-THC signiﬁcantly reduced
the relative percentage of BV-2 microglia that manifest the amoe-
boid phenotype; instead, prompting them to adopt a non-round,
branchedmorphologywith cytoplasmic extensions,most of which
was classiﬁed as being bipolar in shape (Table 1). Other than a
small but signiﬁcant decrease in the relative percentage of unipolar
BV-2 microglia in the presence of 10 nM 9-THC + 100 nM CBD,
9-THC and NAGly produced non-signiﬁcant ﬂuctuations in the
unipolar, tripolar,multipolar, orﬂat categories (Table 1). However,
the morphologic phenotypic shift evoked by 10 nM NAGly and
10 nM 9-THC was antagonized by 100 nM CBD, which is
Table 1 | Percentage of BV2 cell morphologies with vehicle and six treatment groups.
Ameboid Unipolar Biopolar Tripolar Multipolar Flat
Vehicle 43.75 ± 2.2 17.31 ± 1.2 19.81 ± 1.8 6.20 ± 0.8 6.80 ± 1.0 4.54 ± 0.8
PMA 35.44 ± 2.4* 19.59 ± 1.3 24.29 ± 2.0 6.85 ± 1.2 9.43 ± 2.0 4.33 ± 0.5
CBD 40.72 ± 4.3 18.82 ± 1.9 22.08 ± 3.0 5.85 ± 1.6 10.49 ± 2.0 4.13 ± 0.7
NAGly 32.53 ± 2.4* 18.40 ± 1.5 25.84 ± 1.9* 6.81 ± 0.7 8.82 ± 1.6 5.93 ± 1.0
NAGly+CBD 46.84 ± 3.9‡ 17.42 ± 1.8 18.34 ± 2.1‡ 5.09 ± 0.9 7.37 ± 2.1 4.95 ± 1.6
THC 28.90 ± 2.8* 15.68 ± 1.7 33.57 ± 4.0* 6.45 ± 1.9 10.59 ± 2.5 4.81 ± 0.8
THC+CBD 42.82 ± 8.9# 11.89 ± 2.6* 23.61 ± 4.4 4.06 ± 1.7 10.41 ± 4.2 7.20 ± 2.1
Bold* denotes a signiﬁcant difference from vehicle values (p < 0.05). ‡ denotes signiﬁcant difference from NAGly values (p < 0.05). # denotes signiﬁcant difference
from 9-THC values (p < 0.05).
www.frontiersin.org January 2014 | Volume 4 | Article 162 | 3
“fphar-04-00162” — 2014/1/2 — 11:05 — page 4 — #4
McHugh et al. 9-THC, NAGly and microglial phenotype
in keeping with our previous reports of GPR18 pharmacology
(McHugh et al., 2010, 2012a,b; McHugh, 2012). 100 nM CBD
alone had no signiﬁcant effects onBV-2microglial shape (Table 1).
When all branched morphologies are combined and compared to
those cells in the amoeboid morphology, it is clear that there is an
profound effect on the branched verses non-branched phenotype
in the presence of 9-THC and NAGly and that this is reversed
with CBD (Figure 2).
EFFECTS OF9-THC AND NAGly ON BV-2 MICROGLIAL CYTOKINE
RELEASE
Microglia signal and support numerous other cells by secreting
a variety of signaling molecules and growth factors, including
cytokines. Of the forty cytokines quantiﬁed by the Quantibody
array, the production of ﬁve cytokines were signiﬁcantly altered in
BV-2 microglia in a concentration-dependent manner by NAGly
and9-THC.Theywere:Axl,CD40, IGF-I,OPN,andPro-MMP-9
(Figure 3).
Axl is a member of the tyrosine-protein kinase receptor (RTK)
family and activated by the vitamin K-dependent protein, growth-
arrest-speciﬁc 6 (Gas6; Mark et al., 1996). 10 nM and 100 nM
concentrations of NAGly, 100 nM 9-THC and 1 μg/ml LPS
caused a signiﬁcant increase in the basal productionof the cytokine
Axl, while 10 nM 9-THC produced a signiﬁcant reduction
(Figure 3A). CD40 is a co-stimulatory protein and member of the
TNF-receptor superfamily (Chatzigeorgious et al., 2009). 10 nM
and 100 nM concentrations of NAGly and 9-THC together
with 1 μg/ml LPS caused a signiﬁcant increase in the basal pro-
duction of the cytokine CD40 (Figure 3B). IGF-1 activates the
Insulin-like growth factor 1 receptor (IGF1R), which is a receptor
tyrosine kinase present on many cell types in many tissues (Jones
and Clemmons, 1995). 100 nM 9-THC signiﬁcantly increased
basal IGF-1 levels, as did 1 μg/ml LPS, but 10 nM 9-THC
had no effect. On the other hand, 10 nM NAGly produced a
signiﬁcant drop in IGF-1, while 100 nM NAGly produced a sig-
niﬁcant increase (Figure 3C). OPN is expressed in a range of
immune cells, including macrophages, neutrophils, dendritic cells,
and T and B cells (Mazzali et al., 2002). 10 nM and 100 nM
concentrations of NAGly and 9-THC together with 1 μg/ml
LPS caused a signiﬁcant increase in the basal production of the
cytokine OPN (Figure 3D). Pro-MMP-9 is the precursor form
of MMP-9, which degrades type IV and V collagens (Toth et al.,
2003). 10 nM and 100 nM 9-THC signiﬁcantly increased basal
Pro-MMP-9 levels, as did 1 μg/ml LPS and 100 nM NAGly.
On the other hand, 10 nM NAGly produced a signiﬁcant drop
in Pro-MMP-9 (Figure 3E). Changes in cytokine production
levels evoked by10 nM NAGly and 100 nM 9-THC for all
ﬁve cytokines were signiﬁcantly attenuated by 100 nM CBD
(Figures 4A–E).
DISCUSSION
Microglia play crucial roles in the development, on-going activ-
ity and regeneration of the CNS. For example, during CNS
injury, microglia participate in inﬂammation and wound heal-
ing by migrating into damaged tissue, where they proliferate
and act as phagocytic scavengers (Zhang et al., 2003). Microglia
communicate with and support other cells by secreting a variety
of signaling molecules and growth factors (Zhang et al., 2003).
Microglia actively inﬂuence the environment of the CNS and
may act as an essential link in the interaction of cytokines with
neurons (Zhang et al., 2003). They also actively regulate the num-
ber of functional synapses in the CNS and glutamate receptor
FIGURE 2 | Amoeboid versus branched phenotypes. Vehicle (0.1% DMS0), 10 nM PMA, 10 nM NAGly, 100 nM CBD, 10 nM NAGly + 100 nM CBD, 10 nM
9-THC, 10 nM 9-THC + 100 nM CBD. n = 5–15. *p < 0.05, **p < 0.01 (One-way ANOVA).
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FIGURE 3 | Levels of cytokine production after 3 h treatment in BV-2 microglia. (A) Axl, (B) IGF-1, (C) CD40, (D) OPN, (E) Pro-MMP-9. NAGly (10 nM and
100 nM) and 9-THC (10 nM and 100 nM). n = 4–5. *p < 0.05, **p < 0.01, ***p < 0.001 (One-way ANOVA).
expression (Ji et al., 2013). This does not merely take place dur-
ing development, but rather constitutes a dynamic, reversible, and
continuous event in the mature brain. Hence, they are directly
involved in the modulation of synaptic activity (Ji et al., 2013).
In short, microglia are highly complex cells found in the CNS
that exhibit multiple forms and functional specializations, and it
has long been appreciated that microglial cells exist in extremely
different cell shapes ranging from an amoeboid to a ramiﬁed phe-
notype. Indeed, microglial cells adapt their cell morphology to the
meet the functional demands of their microenvironment: amoe-
boid, when they have to eliminate cell debris; ramiﬁed, when
they have to keep their microenvironment under surveillance;
branched cytoplasmic extensions, when they make direct contact
with synaptic elements to modulate activity; and non-polarized,
when they secrete cytokines and reactive oxygen or nitrogen
species. Moreover, the CNS microenvironment also prompts
microglia to adapt their cytokine release proﬁle to meet functional
demands (i.e., pro- versus anti-inﬂammatory). The mechanisms
regulating these adaptations are poorly understood and prompt
the question of what triggers cytological plasticity in microglia.
Our previous research has shown that 9-THC and NAGly are
full agonists at GPR18 with EC50 values in the nanomolar range,
and that NAGly-GPR18 signaling drives potent microglia migra-
tion, proliferation as well as mitogen-activated protein kinase
(MAPK) activation. Given this, we explored the hypothesis that
9-THC and NAGly, putatively also through GPR18 receptors,
regulates morphological and cytokine signaling plasticity in BV-2
microglia.
9-THC AND NAGLY: MORPHOLOGICAL PLASTICITY
Our observations demonstrate that both 9-THC and NAGly
inﬂuenced the shape of BV-2 microglia (Table 1). 10 nM concen-
trations of both molecules signiﬁcantly reduced the proportion
of cells that manifested the amoeboid phenotype by means of
generally increasing the number of cytoplasmic processes branch-
ing off the microglial cell body. These morphological shifts were
prevented by co-treatment with 100 nM CBD, which alone had
no effects. (Pöttler et al., 2006) have reported that the addition
of PMA decreased the number of amoeboid and increased the
number of branched BV-2 microglia in vitro. Our results repro-
duced and conﬁrmed their ﬁndings. A signiﬁcant percentage of
BV-2microglia assumed a bipolar phenotypewhen exposed to9-
THC or NAGly. If the data is simpliﬁed by collapsing the shape
categories into amoeboid versus branched, when exposed to Vh
alone there is an almost equivalent amount of both phenotypes;
however, the addition of PMA, NAGly, and 9-THC signiﬁcantly
shifted the percentage distribution in favor of branched, which was
reversed by co-addition of CBD. This suggests that there may be
a particular functional relevance to the branched morphology in
the neuronal environment of the CNS. In support of this, recent
reports state that non-amoeboidmicroglia contact active synapses,
implying a cell-cell interaction between ramiﬁed microglia and
neurons have also described how ramiﬁed microglia contribute
to the protection of neurons from excitotoxicity (Tremblay et al.,
2010; Fontainhas et al., 2011). Microglia are capable of adapting
their cytoskeleton to adopt any of the six shapes categorized here.
While this morphological plasticity is continuous in the sense that
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FIGURE 4 | Levels of cytokine production after 3 h treatment co-incubation with CBD in BV-2 microglia. (A) Axl, (B) IGF-1, (C) CD40, (D) OPN, (E)
Pro-MMP-9. Cytokine production by BV-2 microglia in response to NAGly (10 nM) and 9-THC (100 nM) ± CBD (100 nM) n = 4–5. **p < 0.01, ***p < 0.001
(One-way ANOVA).
the changes are not binary or quantal, microglia do not neces-
sarily have to progress from amoeboid to unipolar to bipolar to
tripolar. . . etc. The different morphological stages of microglial
activation and their functional consequences have not been fully
ascertained in detail; this is an emerging ﬁeld of interest to which
our data contribute.
9-THC AND NAGly: CYTOKINE SIGNALING PLASTICITY
Cytokines are varied substances (e.g., interferons, interleukins,
growth factors, etc.) that are releasedby certain cells of the immune
system and have an effect on other cells. The secretion proﬁle of
ﬁve cytokines (Axl, CD40, IGF-I, OPN, and Pro-MMP-9) was sig-
niﬁcantly altered in BV-2 microglia by 9-THC and NAGly; the
changes were attenuated by CBD (100 nM). Axl is an enzyme of
the RTK family and is involved in the transduction of signals from
the extracellular matrix to the cytoplasm by binding growth fac-
tors like vitamin K-dependent protein growth-arrest-speciﬁc gene
6 (Gas6; Mark et al., 1996). Axl is involved in the mediation of
cell aggregation by homotypic binding (Heide et al., 1998), which
is an interaction between the same adhesion molecule expressed
by different cell types (e.g., neurons and microglia). Axl signaling
plays a role in cell growth and survival in normal and cancer cells,
including colon cancer and melanoma (Sensi et al., 2011). Inter-
estingly, the ﬁrst report to describe GPR18 arose unanticipated
from expression studies by Gantz et al. (1997), who inadvertently
isolated the GPCR from the human colonic cancer Colo 320DM
cell line. While, Qin et al. (2010) reported that expression levels
of GPR18 were not only constitutively active but also ∼ 24-fold
higher in human metastatic melanoma compared with benign
nevi.
CD40 is a co-stimulatory protein and member of the TNF-
receptor superfamily; it is found on antigen presenting cells and
has been found to be essential in mediating a broad variety
of immune and inﬂammatory responses (Chatzigeorgious et al.,
2009). CD40 helps mediate the induction of potent microbici-
dal substances in glial cells, including reactive oxygen species and
nitric oxide, leading to the destruction of ingested microbes (Cao
et al., 2009). The interaction of this cytokine with TNF receptors
have been found to be necessary for amyloid beta (Aβ)-induced
microglial activation (Tan et al., 2002), and thus is thought to be
an early event in Alzheimer’s disease pathogenesis. IGF-1 acti-
vates the IGF1R, which is a receptor tyrosine kinase present on
many cell types in many tissues (Jones and Clemmons, 1995). It
is a primary mediator of the effects of growth hormone and
one of the most potent natural activators of the AKT signaling
pathway (Gallagher et al., 2010). IGF-1 has growth-promoting
effects on almost every cell in the body; it regulates cellular
growth, development and DNA synthesis, especially in neuronal
cells (Ueno et al., 2013). OPN is expressed in a range of immune
cells, including macrophages, neutrophils, dendritic cells, and T
and B cells (Mazzali et al., 2002). This cytokine is a chemoat-
tractant that promotes cell recruitment to inﬂammatory sites.
OPN also functions as an adhesion protein, involved in cell
attachment and wound healing, and mediates cell activation, cell
survival (by regulating apoptosis) and cytokine production (Maz-
zali et al., 2002). Proteins of the matrix metalloproteinase (MMP)
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family are secreted as inactive pro-MMP proteins and subse-
quently cleaved by extracellular proteinases (Toth et al., 2003).
They are involved in the breakdown of extracellular matrix in
normal physiological processes, such as embryonic development,
reproduction, and tissue remodeling, as well as in disease pro-
cesses, such as arthritis, intracerebral hemorrhage, and metastasis
(Wang andTsirka,2005). MMP-9degrades type IV andV collagens
(Kähäri and Saariaho-Kere, 1997).
While there is general interest in, as well as reports in the litera-
ture andongoing investigations into, the inﬂuence of cannabinoids
on cytokine signaling, this is the ﬁrst data regarding these ﬁve
speciﬁc cytokines inBV-2microglia. A synopsis of the overall func-
tional roles of these ﬁve cytokineswould include growth, adhesion,
tissue remodeling and apoptotic regulation. Their modulation
implies an important role for the underlying mechanism of action
exploited here by 9-THC and NAGly. The effects observed were
concentration-dependent, where the most extreme differences in
response between 10 nM and 100 nM of NAGly and 9-THC
were: decreased versus increased IGF-1 and Pro-MMP-9 basal lev-
els for NAGly; and decreased/no change versus increased IGF-1
and Axl basal levels for 9-THC. Antagonism of 9-THC and
NAGly effects by 100 nM CBD is in keeping with our previous
reports of GPR18 pharmacology (McHugh et al., 2010, 2012a,b).
Further investigation is needed to fully ascertain the involvement
of GPR18 and to rule in or rule out other potentially relevant
receptors (i.e., CB1, CB2, GPR92). A time course study leading
up to and continuing beyond the time points used here would be
beneﬁcial in determining when and to what extent does maximal
cytoplasmic branching and cytokine release induced by 9-THC
and NAGly occur in the BV-2 cells. This would also help clarify the
apparent switching of some of the cytokines from below basal to
above basal levels (e.g., IGF-1 at 10 nM and 100 nM 9-THC and
NAGly), as would tests with additional concentrations. Cytokine
signaling is known to be complex, and often includes opposing
responses (e.g., pro- versus anti-inﬂammatory) that are consid-
ered to be physiologically routine. Alternatively, ligand-receptors
interactions at GPCRs are often subject to desensitization, which
may explain the differential effects observed. As mentioned above,
it is also possible that 9-THC and NAGly are acting via multiple
receptors to produce a form of physiological antagonism with
respect to cytokine release.
The ﬁndings in this study support our hypothesis that 9-THC
and NAGly, putatively through GPR18 receptors, regulate mor-
phological and cytokine signaling plasticity in BV-2 microglia.
These data add to an emerging proﬁle that emphasizes NAGly
as a component of an endogenous system present in the CNS
that tightly integrates microglial proliferation, recruitment, and
adhesion with neuron-glia interactivity and tissue remodeling.
A greater understanding of this system is essential to improving
our ability to therapeutically monitor and manage dysregulated
microglial activity.
AUTHOR CONTRIBUTIONS
Douglas McHugh: cytokine experiments; BV-2 microglia shape
categorization; design and coordination of the studies; data inter-
pretation; statistical analyses; and manuscript preparation. Daniel
Roskowski: morphology experiments and BV-2 microglia shape
categorization and quantiﬁcation, data interpretation; statistical
analyses. Sisi Xie: BV-2 microglia shape categorization and quan-
tiﬁcation. Heather B. Bradshaw: design and coordination of the
studies; data interpretation; statistical analyses; and manuscript
preparation. All authors read and approved the ﬁnal manuscript.
ACKNOWLEDGMENTS
This work was supported by NIH DA018224. We thank Anisa
Curry-Vietze, Hannah Kasak-Gliboff, and Harpo Roeder for their
work on validating the cell morphology phenotyping assay.
REFERENCES
Begg, M., Pacher, P., Bátkai, S., Osei-Hyiaman, D., Offertáler, L., Mo, F. M., et al.
(2005). Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106,133–145.
doi: 10.1016/j.pharmthera.2004.11.005
Blasi, E., Barluzzi, R., Bocchini, V., Mazzolla, R., and Bistoni, F. (1990). Immor-
talization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J.
Neuroimmunol. 27, 229–237. doi: 10.1016/0165-5728(90)90073-V
Block, M. L., Zecca, L., and Hong, J.-S. (2007). Microglia-mediated neurotoxic-
ity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69. doi:
10.1038/nrn2038
Bradshaw, H., Rimmerman, N., Hu, S., Benton, V., Stuart, J., Masuda, K., et al.
(2009). The endocannabinoid anandamide is a precursor for the signaling lipid
N-arachidonoyl glycine by two distinct pathways. BMC Biochem. 10:14. doi:
10.1186/1471-2091-10-14
Cao, L., Plamer, C. D., Malon, J. T., and De Leo, J. A. (2009). Critical role of
microglial CD40 in the maintenance of mechanical hypersensitivity in a murine
model of neuropathic pain. Eur. J. Immunol. 39, 3562–3569. doi: 10.1002/eji.200
939657
Carson, M. J. (2002). Microglia as liaisons between the immune and central nervous
systems: functional implications for multiple sclerosis. Glia 40, 218–231. doi:
10.1002/glia.10145
Chatzigeorgious, A., Lyberi, M., Chatzilymperis, G., Nezos, A., and Kamper,
E. (2009). CD40/CD40: signaling and its implications in health and disease.
BioFactors 35, 474–483. doi: 10.1002/biof.62
Colton, C., and Wilcock, D. (2010). Assessing activation states in microglia.
CNS Neurol. Disord. Drug. Targets 9, 174–191. doi: 10.2174/1871527107910
12053
Danton,G.H., andDietrich,W.D. (2003). Inﬂammatorymechanisms after ischemia
and stroke. J. Neuropathol. Exp. Neurol. 62,127–136.
Eikelenboom, P., Bate, C., Van Gool, W. A., Hoozemans, J. J., Rozemuller. J. M.,
Veerhuis, R., et al. (2002). Neuroinﬂammation in Alzheimer’s disease and prion
disease. Glia 40, 232–239. doi: 10.1002/glia.10146
Fetler, L., and Amigorena, S. (2005). Neuroscience. Brain under surveillance: the
microglia patrol. Science 309, 392–393. doi: 10.1126/science.1114852
Fontainhas, A. M., Wang, M., Liang, K. J., Chen, S., Mettu, P., Damani, M., et al.
(2011). Microglial morphology and dynamic behavior is regulated by ionotropic
glutamatergic and GABAergic neurotransmission. PLoS ONE 6:e15973. doi:
10.1371/journal.pone.0015973
Gallagher, E. J., Fierz, Y., Ferguson, R. D., and LeRoith, D. (2010). The pathway from
diabetes and obesity to cancer, on the route to targeted therapy. Endocr. Pract. 16,
864–873. doi: 10.4158/EP10098.RA
Gantz, I., Muraoka, A., Yang, Y.-K., Samuelson, L. C., Zimmerman, E. M., and
Cook, H. et al. (1997). Cloning and chromosomal localization of a gene (GPR18)
encoding a novel seven transmembrane receptor highly expressed in spleen and
testis. Genomics 42, 462–466. doi: 10.1006/geno.1997.4752
Garden, G. A., and Moller, T. (2006). Microglia biology in health and disease. J
Neuroimmune Pharmacol. 1, 127–137. doi: 10.1007/s11481-006-9015-5
Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. 3,
23–35. doi: 10.1038/nri978
Heide, I., Sokoll, A. C., Henz, B. M., Nagel, S., Kreissig, K., Grützkau, A., et al.
(1998). Regulation and possible function of axl expression in immature human
mast cells. Ann. Hematol. 77, 199–205. doi: 10.1007/s002770050443
Járai, Z., Wagner, J. A., Varga, K. R., Lake, K. D., Compton, D. R., Martin, B. R., et al.
(1999). Cannabinoid-induced mesenteric vasodilation through an endothelial
www.frontiersin.org January 2014 | Volume 4 | Article 162 | 7
“fphar-04-00162” — 2014/1/2 — 11:05 — page 8 — #8
McHugh et al. 9-THC, NAGly and microglial phenotype
site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 96, 14136–
14141. doi: 10.1073/pnas.96.24.14136
Ji, K., Akgul, G., Wollmuth, L. P., and Tsirka, S. E. (2013). Microglia
actively regulate the number of functional synapses. PLoS ONE 8:e56293.
doi:10.1371/journal.pone.0056293
Jones, J. I., and Clemmons, D. R. (1995). Insulin-like growth factors and their
binding proteins: biological actions. Endocr. Rev. 16, 3–34.
Kähäri,V.-M., and Saariaho-Kere,U. (1997). Matrixmetalloproteinases in skin. Exp.
Dermatol. 6, 199–213. doi: 10.1111/j.1600-0625.1997.tb00164.x
Kohno, M., Hasegawa, H., Inoue, A., Muraoka, M., Miyazaki, T., Oka, K., et al.
(2006). Identiﬁcation of N-arachidonylglycine as the endogenous ligand for
orphan G-protein-coupled receptor GPR18. Biochem. Biophyl. Res. Comm. 347,
827–832. doi: 10.1016/j.bbrc.2006.06.175
Mackie, K., and Stella, N. (2006). Cannabinoid receptors and endocannabinoids:
Evidence for new players. AAPS J. 8, E298–E306.
Mark, M. R., Chen, J., Hammonds, R. G., Sadick, M., and Godowsk, P. J. (1996).
Characterization of Gas6, a member of the superfamily of G domain-containing
proteins, as a ligand for Rse and Axl. J. Biol. Chem. 271, 9785–9789. doi:
10.1074/jbc.271.16.9785
Mazzali, M., Kipari, T., Ophascharoensuk, V., Wesson, J. A., Johnson, R., and
Hughes, J. (2002). Osteopontin – a molecule or all seasons. Q. J. Med. 95, 3–13.
doi: 10.1093/qjmed/95.1.3
McHugh, D., Hu, S. S.-J., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., et al.
(2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives
directed cellular migration through GPR18, the putative abnormal cannabidiol
receptor. BMC Neurosci. 11:44. doi: 10.1186/1471-2202-11-44
McHugh, D. (2012). GPR18 in microglia: implications for the CNS and
endocannabinoid system signalling. Br. J. Pharmacol. 167, 1575–1582. doi:
10.1111/j.1476-5381.2012.02019.x
McHugh, D., Page, J., Dunn, E., and Bradshaw, H. B. (2012a). (9-THC and N-
arachidonoyl glycine are full agonists at GPR18 and cause migration in the
human endometrial cell line, HEC-1B. Br. J. Pharmacol. 165, 2414–2424. doi:
10.1111/j.1476-5381.2011.01497.x
McHugh, D., Wager-Miller, J., Page, J., and Bradshaw, H. B. (2012b). siRNA knock-
down of GPR18 receptors in BV-2 microglia attenuates the cell migration induced
by N-arachidonyl glycine. J. Mol. Signal. 7, 10. doi: 10.1186/1750-2187-7-10
Oh, D. Y., Yoon, J. M., Moon, M. J., Hwang, J. I., Choe, H., Lee, J. Y.,
et al. (2008). Identiﬁcation of farnesyl pyrophosphate and N-arachidonylglycine
as endogenous ligands for GPR92. J. Biol. Chem. 283, 21054–21064. doi:
10.1074/jbc.M708908200
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V.,
Elphick, M. R. et al. (2010). International union of basic and clinical pharma-
cology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2.
Pharmacol. Rev. 62, 588–631. doi: 10.1124/pr.110.003004
Pöttler, M., Zierler, S., and Kerschbaum, H. H. (2006). An artiﬁcial three-
dimensional matrix promotes ramiﬁcation in the microglial cell-line, BV-2.
Neurosci. Lett. 410, 137–140. doi: 10.1016/j.neulet.2006.09.082
Qin, Y., Verdegaal, E. M. E., Siderius, M., Bebelman, J. P., Smit, M. J., and Leurs,
R., et al. (2010). Quantitative expression proﬁling of G-protein-coupled recep-
tors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR
GPR18 as novel drug target. Pigment Cell Melanoma Res. 24, 207–218. doi:
10.1111/j.1755-148X.2010.00781.x
Raivich, G. (2005). Like cops on the beat: the active role of resting microglia. Trends
Neurosci. 28, 571–573. doi: 10.1016/j.tins.2005.09.001
Sensi, M., Catani, M., Castellano, G., Nicolini, G., Alciato, F., Tragni, G., et al.
(2011). Human cutaneous melanomas lacking MITF and melanocyte differenti-
ation antigens express a functional Axl receptor kinase. J. Invest. Dermatol. 131,
2448–2457. doi: 10.1038/jid.2011.218
Streit, W. J. (2002). Microglia as neuroprotective, immunocompetent cells of the
CNS. Glia 40, 133–139. doi: 10.1002/glia.10154
Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., et al.
(2002). Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat.
Neurosci. 5, 1288–1293. doi: 10.1038/nn968
Toth, M., Chvyrkova, I., Bernardo, M. M., Hernandez-Barrantes, S., and Fridman,
R. (2003). Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3:
role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 308,
386–395. doi: 10.1016/S0006-291X(03)01405-0
Tremblay, M. E., Lowery, R. L., and Majewska, A. K. (2010). Microglial interac-
tions with synapses are modulated by visual experience. PLoS Biol. 8:e1000527.
doi:10.1371/journal.pbio.1000527
Ueno, M., Fujita, Y., Tanaka, T., Nakamura, Y., Kikuta, J., Ishii, M., et al. (2013).
Layer V cortical neurons require microglial support for survival during postnatal
development. Nat. Neurosci. 16, 543–551. doi: 10.1038/nn.3358
van Rossum, D., and Hanisch, U-K. (2004). Microglia. Metab. Brain Dis. 19, 393–
411. doi: 10.1023/B:MEBR.0000043984.73063.d8
Walter, L., Franklin, A., Witting, A., Wade, C,. Xie, Y., Kunos, G., Mackie, K., and
Stella, N. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell
migration. J. Neurosci. 23, 1398–1405.
Wang, J., and Tsirka, S. E. (2005). Neuroprotection by inhibition of matrix met-
alloproteinases in a mouse model of intracerebral haemorrhage. Brain 128,
1622–1633. doi: 10.1093/brain/awh489
Zhang, J., Geula, C., Lu, C., Koziel, H., Hatcher, L. M., Roisen, F. J.
(2003). Neurotrophins regulate proliferation and survival of two microglial
cell lines in vitro. Exp. Neurol. 183, 469–481. doi: 10.1016/S0014-4886(03)
00222-X
Conflict of Interest Statement:The authors declare that the research was conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 31 August 2013; paper pending published: 31 October 2013; accepted: 09
December 2013; published online: 02 January 2014.
Citation: McHugh D, Roskowski D, Xie S and Bradshaw HB (2014) 9-THC and
N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release
plasticity: implications for signaling at GPR18. Front. Pharmacol. 4:162. doi:
10.3389/fphar.2013.00162
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Pharmacology.
Copyright © 2014 McHugh, Roskowski, Xie and Bradshaw. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, pro-
vided the original author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | Neuropharmacology January 2014 | Volume 4 | Article 162 | 8
